Insulin Resistance in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Alpelisib Pilot & Feasibility Study
Sponsor: |
Dr. Joshua Cook |
Enrolling: |
Male and Female Patients |
Study Length: |
4 Days |
Clinic Visits: |
2 |
IRB Number: |
AAAU3423 |
U.S. Govt. ID: |
NCT05733455 |
Contact: |
Zachary Sone: 212-305-9336 / zds2120@cumc.columbia.edu |
We are recruiting healthy volunteers, aged 18-65, for a research study on the buildup of excessive liver fat ("fatty liver disease") in people with or at risk for type 2 diabetes because their bodies are resistant to the actions of the blood sugar-lowering hormone, insulin. To do this, we seek to induce temporary insulin resistance in 10-12 healthy volunteers using one dose of either a placebo (inactive drug) or a medication called alpelisib (brand name: Piqray), which is a treatment for certain breast cancers. We will then measure the effect of treatment on blood sugar, insulin, and fat levels during fasting and after drinking a sugary beverage. Participants will receive compensation for their participation, including a stipend (salary) of $300 and reimbursement for travel expenses.
This study is closed
Investigator
Joshua Cook, MD, PhD
Do you have any known chronic health problems, including overweight or obesity? |
Yes |
No |
Do you take any medications regularly, other than vitamin/mineral supplements or birth control? |
Yes |
No |
Will you be able to attend two visits (one of 1-2 hours, and one of 4 hours) at 8:00 AM, three days apart? |
Yes |
No |
Are you okay with having your blood drawn? |
Yes |
No |
Are you pregnant, breastfeeding, or trying to get pregnant? |
Yes |
No |